Company profile for Beacon Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to restore and improve the vision of patients with a range of prevalent and rare retinal diseases that result in blindness. The Company has an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP) with two preclinical programs, one targeting dry age-related macular degeneration (A...
Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to restore and improve the vision of patients with a range of prevalent and rare retinal diseases that result in blindness. The Company has an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP) with two preclinical programs, one targeting dry age-related macular degeneration (AMD) and another in-licensed from the University of Oxford targeting cone-rod dystrophy (CRD). Lead development candidate AGTC-501, is a gene therapy program in Phase II clinical trials for the treatment of XLRP.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
Rolling Stock Yard, 2nd floor 188 York Way Kings Cross London, N7 9AS
Telephone
Telephone
+44 (0)203 3987880
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/12/3186150/30580/en/Beacon-Therapeutics-to-Participate-in-the-Jefferies-Global-Healthcare-Conference.html

GLOBENEWSWIRE
12 Nov 2025

https://www.globenewswire.com/news-release/2025/10/15/3167016/30580/en/Beacon-Therapeutics-to-Participate-in-Chardan-s-9th-Annual-Genetic-Medicines-Conference.html

GLOBENEWSWIRE
15 Oct 2025

https://www.globenewswire.com/news-release/2025/09/10/3147700/30580/en/Beacon-Therapeutics-to-Participate-in-the-2025-Bank-of-America-Healthcare-Trailblazers-Private-Company-Conference.html

GLOBENEWSWIRE
10 Sep 2025

https://www.globenewswire.com/news-release/2025/09/04/3144423/30580/en/Beacon-Therapeutics-Announces-Positive-Interim-9-Month-Results-from-DAWN-Trial-and-36-Month-Phase-2-SKYLINE-Trial-Data-for-Laru-zova-in-Patients-with-X-linked-Retinitis-Pigmentosa-.html

GLOBENEWSWIRE
04 Sep 2025

https://www.globenewswire.com/news-release/2025/08/21/3137058/30580/en/Beacon-Therapeutics-Announces-EURETINA-2025-Presentations-on-9-Month-Phase-2-DAWN-and-36-Month-Phase-2-SKYLINE-Trial-Data-for-laru-zova-in-Patients-with-X-linked-Retinitis-Pigmento.html

GLOBENEWSWIRE
21 Aug 2025

https://www.globenewswire.com/news-release/2025/07/08/3111668/30580/en/Beacon-Therapeutics-completes-enrollment-in-registrational-Phase-2-3-VISTA-trial-of-laru-zova-for-patients-with-XLRP.html

GLOBENEWSWIRE
08 Jul 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty